Eagle Pharmaceuticals to Present at June Investor Conferences

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows:

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows:

Conference:

Jefferies Virtual Healthcare Conference

Date:

Thursday, June 4, 2020

Time:

1:00 p.m. ET

Webcast:

http://wsw.com/webcast/jeff126/egrx/

Conference:

William Blair Virtual 40th Annual Growth Stock Conference

Date:

Thursday, June 11, 2020

Time:

10:00 a.m. CT / 11:00 a.m. ET

Webcast:

http://www.wsw.com/webcast/blair56/egrx

The presentations will be webcast live at the aforementioned times, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors section.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Public Relations for Eagle Pharmaceuticals, Inc.:
Rose Ramseth
WE Communications
T: 212-551-4841
M: 206-898-7551
E: rramseth@we-worldwide.com

Source: Eagle Pharmaceuticals, Inc.

MORE ON THIS TOPIC